{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:19:06Z","timestamp":1792271946156,"version":"4.4.0"},"reference-count":32,"publisher":"FapUNIFESP (SciELO)","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arq. Gastroenterol."],"abstract":"<jats:p>ABSTRACT  BACKGROUND:  Direct-acting antivirals have revolutionized hepatitis C treatment, also for patients with chronic kidney disease (CKD), but some controversy exists regarding the use of sofosbuvir (SOF) in patients with glomerular filtration rate (GFR) &lt;30 mL\/min.  OBJECTIVE:  To evaluate the efficacy and safety of these regimens for hepatitis C treatment of patients with CKD and after renal transplantation, as well as the impact of SOF on renal function in non-dialysis patients.  METHODS:  All patients with hepatitis C and CKD or renal transplant treated with direct-acting antivirals at a referral center in Brazil between January 2016 and August 2017 were included. Efficacy was evaluated based on viral load (HCV RNA) and a sustained virological response (SVR) consisting of undetectable RNA 12 and\/or 24 weeks after the end of treatment (SVR12 and SVR24) was defined as cure. Safety was determined by adverse events and ribavirin, when combined, was administered in escalating doses to all patients with GFR &lt;60 mL\/min. The impact of SOF on renal function was determined by the measurement of baseline creatinine during and after the end of treatment and its increase was evaluated using the Acute Kidney Injury Network (AKIN) classification.  RESULTS:  A total of 241 patients (52.7% females) with a mean age of 60.72\u00b110.47 years were included. The combination of SOF+daclatasvir was the predominant regimen in 75.6% of cases and anemia was present in 28% of patients who used ribavirin (P=0.04). The SVR12 and SVR24 rates were 99.3% and 97.1%, respectively. The treatment was well tolerated and there were no major clinically relevant adverse events, with the most prevalent being asthenia (57.7%), itching (41.1%), headache (40.7%), and irritability (40.2%). Among conservatively treated and renal transplant patients, oscillations of creatinine levels (AKIN I) were observed in 12.5% of cases during treatment and persisted in only 8.5% after the end of treatment. Of these, 2.0% had an initial GFR &lt;30 mL\/min and this percentage decreased to 1.1% after SOF use. Only 0.5% and 1.6% of the patients progressed to AKIN II and AKIN III elevation, respectively.  CONCLUSION:  The direct-acting antivirals were safe and efficacious in CKD patients treated with SOF-containing regimens, with the observation of high SVR rates, good tolerability and few severe adverse events. The combination with ribavirin increased the risk of anemia and the administration of escalating doses seems to be useful in patients with GFR &lt;60 mL\/min. In patients with GFR &lt;30 mL\/min, SOF had no significant renal impact, with serum creatinine returning to levels close to baseline after treatment.<\/jats:p>","DOI":"10.1590\/s0004-2803.202000000-09","type":"journal-article","created":{"date-parts":[[2020,2,25]],"date-time":"2020-02-25T15:37:24Z","timestamp":1582645044000},"page":"45-49","source":"Crossref","is-referenced-by-count":9,"title":["HEPATITIS C TREATMENT OF RENAL TRANSPLANT AND CHRONIC KIDNEY DISEASE PATIENTS: EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL REGIMENS CONTAINING SOFOSBUVIR"],"prefix":"10.1590","volume":"57","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0581-4487","authenticated-orcid":false,"given":"Fernanda Bellini Lunardi","family":"MICHELS","sequence":"first","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8290-7073","authenticated-orcid":false,"given":"Ana Cristina de Castro","family":"AMARAL","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9795-5705","authenticated-orcid":false,"given":"Roberto Jos\u00e9 de","family":"CARVALHO-FILHO","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0186-388X","authenticated-orcid":false,"given":"Gustavo de Almeida","family":"VIEIRA","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8639-6963","authenticated-orcid":false,"given":"Ana Lucia da Silva","family":"SOUZA","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8992-8494","authenticated-orcid":false,"given":"Maria Lucia Gomes","family":"FERRAZ","sequence":"additional","affiliation":[{"name":"Universidade Federal de S\u00e3o Paulo,  Brasil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"530","published-online":{"date-parts":[[2020,2]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2147\/IJGM.S127689","article-title":"Hepatitis C treatment: where are we now?","volume":"10","author":"Burstow NJ","year":"2017","journal-title":"Int J Gen Med"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12879-018-3125-6","article-title":"Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study","volume":"18","author":"Lanini S","year":"2018","journal-title":"BMC Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1111\/liv.13626","article-title":"Treatment of hepatitis C: the use of the new pangenotypic direct-acting antivirals in \u201cspecial populations\u201d","volume":"38","author":"Pol S","year":"2018","journal-title":"Liver Int"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1111\/tri.12360","article-title":"Hepatitis C virus infection in end-stage renal disease and kidney transplantation","volume":"27","author":"Burra P","year":"2014","journal-title":"Transpl Int"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/liv.13102","article-title":"Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function","volume":"36","author":"Saxena V","year":"2016","journal-title":"Liver Int"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40262-015-0261-7","article-title":"Pharmacokinetic, pharmacodynamic, and drug-interaction profile of the hepatitis C virus NS5B polymerase inhibitor Sofosbuvir","volume":"54","author":"Kirby BJ","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"ref7","series-title":"Protocolo Cl\u00ednico e Diretrizes Terap\u00eauticas para Hepatite C e Coinfec\u00e7\u00f5es","year":"2015"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"727","DOI":"10.5604\/01.3001.0010.2717","article-title":"Treatment of Chronic HCV Infection with the New Direct Acting Antivirals (DAA): First Report of a Real World Experience in Southern Brazil","volume":"16","author":"Cheinquer H","year":"2017","journal-title":"Ann Hepatol"},{"key":"ref9","article-title":"Direct antiviral therapy for treatment of hepatitis C: A real-world study from Brazil","author":"Lobato CMO","year":"2019","journal-title":"Ann Hepatol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/00007691-200212000-00004","article-title":"Dosage of ribavirin in patients with hepatitis C should be based on renal function: a population pharmacokinetic analysis","volume":"24","author":"Bruchfeld A","year":"2002","journal-title":"Ther Drug Monit"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1128\/AAC.00608-13","article-title":"Safety, Tolerability, and Pharmacokinetics of Ribavirin in Hepatitis C Virus-Infected Patients with Various Degrees of Renal Impairment","volume":"57","author":"Brennan BJ","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/ki.2014.328","article-title":"The definition of acute kidney injury and its use in practice","volume":"87","author":"Thomas ME","year":"2015","journal-title":"Kidney Int"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"531","DOI":"10.5301\/ijao.5000613","article-title":"Direct-acting antivirals for hepatitis C virus in patients on maintenance dialysis","volume":"40","author":"Fabrizi F","year":"2017","journal-title":"Int J Artif Organs"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"833","DOI":"10.4254\/wjh.v9.i19.833","article-title":"Opportunities for treatment of the hepatitis C virus-infected patient with chronic kidney disease","volume":"9","author":"Ladino M","year":"2017","journal-title":"World J Hepatol"},{"key":"ref15","first-page":"320","article-title":"Novel treatment of hepatitis C virus infection for patients with renal impairment","volume":"4","author":"Suda G","year":"2016","journal-title":"J Clin Transl Hepatol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/jvh.12681","article-title":"Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories","volume":"24","author":"Mendizabal M","year":"2017","journal-title":"J Viral Hepat"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1111\/liv.13336","article-title":"Efficacy and safety of direct-acting antivirals-based antiviral therapies for hepatitis C virus patients with stage 4-5 chronic kidney disease: a meta-analysis","volume":"37","author":"Li T","year":"2017","journal-title":"Liver Int"},{"key":"ref18","first-page":"2065","article-title":"Sofosbuvir-based antiviral therapy in hepatitis C virus patients with severe renal failure","volume":"32","author":"Dumortier J","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"ref19","article-title":"Efficacy and safety of direct acting antivirals in kidney transplant recipients with chronic hepatitis C virus infection","volume":"11","author":"Lin MV","year":"2016","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40264-016-0420-2","article-title":"Pharmacokinetics, Efficacy, and Safety of Hepatitis C Virus Drugs in Patients with Liver and\/or Renal Impairment","volume":"39","author":"Smolders EJ","year":"2016","journal-title":"Drug Saf"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14740338.2016.1221396","article-title":"New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs)","volume":"15","author":"Scavone C","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1007\/s11096-017-0552-1","article-title":"Adverse effects of direct acting antiviral-based regimens in chronic hepatitis C patients: a Brazilian experience","volume":"39","author":"Medeiros T","year":"2017","journal-title":"Int J Clin Pharm"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"16184","DOI":"10.3748\/wjg.v20.i43.16184","article-title":"Ribavirin induced hemolysis: A novel mechanism of action against chronic hepatitis C virus infection","volume":"20","author":"Soota K","year":"2014","journal-title":"World J Gastroenterol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.2174\/092986706778773059","article-title":"Ribavirin-induced anemia: Mechanisms, risk factors and related targets for future research","volume":"13","author":"Russmann S","year":"2006","journal-title":"Curr Med Chem"},{"key":"ref25","doi-asserted-by":"crossref","DOI":"10.1111\/jvh.12015","article-title":"Low glomerular filtration rate is a risk factor for ribavirina associated anaemia in old patients with chronic hepatitis C","volume":"20","author":"Borroni G","year":"2013","journal-title":"J Viral Hepat"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/apt.14117","article-title":"The frequency of acute kidney injury in patients with chronic hepatitis C virus infection treated with sofosbuvir-based regimens","volume":"46","author":"Maan R","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/liv.13025","article-title":"Sofosbuvir and simeprevir in hepatitis C genotype 1-patients with end-stage renal disease on haemodialysis or GFR <30 mL\/min","volume":"36","author":"Nazario HE","year":"2015","journal-title":"Liver Int"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"924","DOI":"10.3109\/23744235.2015.1078908","article-title":"Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency","volume":"47","author":"Hundemer GL","year":"2015","journal-title":"Infect Dis"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/jcpt.12697","article-title":"Renal safety after one year of sofosbuvir-based therapy for chronic hepatitis C: A Brazilian \u201creal-life\u201d study","volume":"43","author":"Medeiros T","year":"2018","journal-title":"J Clin Pharm Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.jhep.2016.02.044","article-title":"Pharmacokinetics, safety and efficacy of a full dose sofosbuvir-based regimen given daily in hemodialysis patients with chronic hepatitis C","volume":"65","author":"Desnoyer A","year":"2016","journal-title":"J Hepatol"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1111\/jvh.12867","article-title":"Impact of interferon-free regimens on the glomerular filtration rate during treatment of chronic hepatitis C in a real-life cohort","volume":"25","author":"\u00c1lvarez-Ossorio MJ","year":"2018","journal-title":"J Viral Hepat"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.2215\/CJN.02510317","article-title":"Effect of Sofosbuvir-Based Hepatitis C Virus Therapy on Kidney Function in Patients with CKD","volume":"12","author":"Sise ME","year":"2017","journal-title":"Clin J Am Soc Nephrol"}],"container-title":["Arquivos de Gastroenterologia"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/ag\/v57n1\/1678-4219-ag-s0004280320200000009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T17:24:17Z","timestamp":1611422657000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0004-28032020000100045&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["S0004-28032020000100045"],"URL":"https:\/\/doi.org\/10.1590\/s0004-2803.202000000-09","relation":{},"ISSN":["1678-4219","0004-2803"],"issn-type":[{"value":"1678-4219","type":"electronic"},{"value":"0004-2803","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]}}}